Medibank Private Ltd (ASX:MPL) is one of Australia's largest private health insurers, operating the Medibank and ahm brands. Through its Medibank Health division, including Amplar Health, it also provides health services such as GP consultations, telehealth and care in the community. The company says it is trusted by around 6 million people with their health and wellbeing. David Koczkar is Chief Executive Officer.

On 2 October 2026, Medibank shares were trading at $4.57, up 1.33% for the session. The company's 2026 full-year results, released in August, reported growth in underlying profit, policyholders and health services, along with a higher ordinary dividend.

The company is marking 50 years of supporting the health and wellbeing of people in Australia, and it says it is pursuing a set of 2030 ambitions that include growing as a health company beyond insurance.

Medibank says it is accelerating Investment in technology and AI to improve how it works and delivers customer experiences, while keeping clinical quality and safety at the centre.

Key Updates From the Latest Release

Medibank released its 2026 full-year results on 20 August 2026. Key figures include:

  • Underlying net profit after tax increased 2.9% to $636.8 million, and underlying EPS rose 2.9% to 23.1 cents.
  • Group operating profit rose 6.7% to $813.5 million.
  • Net investment income was $178.9 million, down 13.9%.
  • NPAT attributable to shareholders increased 27.5% to $638.7 million.
  • Total claims paid were about $6.9 billion.
  • Net resident policyholder growth was 22,100, or 1.1%, while non-resident policy units declined by 8,200, or 2.3%.
  • The fully franked final ordinary Dividend was 10.9 cents per share, bringing the FY26 ordinary dividend to 19.2 cents, up 6.7%, an 83.0% Payout Ratio within the 75% to 85% target range.

Mr Koczkar said the result reflected improved momentum in the Medibank brand, ahm growing above the market and another record result from Medibank Health. He said people continue to prioritise their health even as household budgets remain under pressure. The company delivered a further $10 million in productivity savings, bringing the total to $132.4 million in under a decade, and its claims payout ratio remains above the industry average.

Medibank said it delivered almost $300 million in value to customers through its Members' Choice and no gap networks and Live Better rewards. More than half of its Health Insurance customers now engage with its health and wellbeing offerings. Amplar Health supported 5.3 million patient interactions, including 4.1 million GP consults, and its online doctor service is now available to the broader community. After the government's bulk billing reforms, the number of GP clinics in its network charging no out-of-pocket fees increased by 56%. Community-based services saved 194,000 hospital bed days, and the company provided a further $40 million to private hospitals.

By brand, Medibank added 8,600 net resident policyholders and ahm added 13,500. The Acquisition rate rose 10 basis points to 11.6%. The company noted that cost-of-living pressures have led to growth skewed to lower product tiers, higher switching and a larger share of joins through aggregators. Non-recurring cybercrime costs were $34.9 million, relating to IT security uplift and legal and regulatory matters from the 2022 cybercrime event, with FY27 costs expected to be less than $20 million. The ex-dividend date was 2 September 2026, with payment on 8 October 2026.

Mr Koczkar said affordability is a present-day challenge, noting that one in four people in Australia say they have delayed or avoided seeing a GP because of cost. He said the health system is under more strain and that Medibank believes the system needs to shift from funding illness to funding health. Customer satisfaction measures included an average Group blended journey NPS of 21.9, and 1 million or more Medibank resident policyholders are engaged members of Live Better. Live Better has delivered around $135 million in value since launch, and the company said it is a reason one in three people choose Medibank.

Points of Caution

Medibank has noted that cost-of-living pressures are pushing customers to lower product tiers and increasing switching, which could weigh on Revenue per policy. Competition in private health insurance is intensifying, and aggregators are taking a larger share of new joins.

Regulatory investigations and litigation related to the 2022 cybercrime event remain ongoing, and the company's cost estimates exclude any potential findings or outcomes. Net investment income declined and can vary with markets. Premium increases require government approval, and changes to health policy could affect the business. Claims Inflation and hospital costs are additional considerations.

The shift toward lower product tiers may reduce average premium revenue, and switching between insurers could increase acquisition costs.

What Lies Ahead

Investors may watch for payment of the final dividend on 8 October 2026, policyholder growth trends across Medibank and ahm, and further expansion of Amplar Health and community-based care. Developments in regulatory investigations and litigation, the annual premium round and progress toward the company's 2030 ambitions may also be relevant.

Investors may also watch the performance of the non-resident policy segment, which declined in FY26, and the company's progress in reducing cybercrime-related costs below the $20 million expected for 2027. Developments in government health policy, including private health insurance settings and bulk billing reforms, may influence the operating environment. Commentary on the acquisition rate across the Medibank and ahm brands will also be followed.

In Summary

Medibank's FY26 result showed growth in operating profit, policyholders and health services, alongside a higher ordinary dividend. Cost-of-living pressures, competition and the cybercrime-related legal matters are likely to remain key areas to follow.